Are you already a client or interested in our services? We are happy to help you.
For Private Banking and Professional Solutions
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37
Belgium
+32 (0)32 86 69 80
Switzerland
+41 (0)43 377 11 11
For Investment Management:
For Investment Banking:
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00
United States of America
+1 (0)21 237 601 34
Newron Pharmaceuticals
Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain.
- Placement of 2,000,000 new shares, representing 12.6% of Newron’s pre-deal outstanding share capital
- Issue price of CHF 13.50 per share resulting in gross proceeds of CHF 27.0 million
- Strong indications of interest were received during a market sounding exercise prior to transaction launch
- The accelerated book-building process generated strong demand from US and European Life Sciences specialist and generalist investors, resulting in a multiple times oversubscribed order book
- Transaction proceeds will be used for the company’s operations, research programs and the development of the company’s current and future pipeline products with a focus on its schizophrenia drug Evenamide
- Kempen acted as Joint Global Coordinator and Joint Bookrunner in this transaction